Incyte, Calithera join for arginase inhibitor | Chemical & Engineering News
Volume 95 Issue 6 | p. 13 | Concentrates
Issue Date: February 6, 2017

Incyte, Calithera join for arginase inhibitor

Department: Business
Keywords: drug development, Incyte, arginase inhibitor, oncology, hematology

Incyte and Calithera Biosciences will work together to develop Calithera’s small-molecule arginase inhibitor CB-1158. Incyte will pay Calithera $45 million up front and make an $8 million equity investment. Calithera could receive up to $750 million in milestone payments. The molecule is being tested alone in early-stage hematology and oncology trials. The companies also expect to explore its use in combination with immuno-oncology agents such as anti-PD-1 therapies.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment